Get the Stockscreener App
15.82
0.81%
-0.21
Avalo Therapeutics Inc stock is traded at $15.82, with a volume of 127.38K.
It is down -0.81% in the last 24 hours and down -9.45% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$16.03
Open:
$16.12
24h Volume:
127.38K
Relative Volume:
0.37
Market Cap:
$288.51M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00448
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
-10.72%
1M Performance:
-9.45%
6M Performance:
+220.56%
1Y Performance:
+99.25%
1-Day Range:
$15.70
$16.38
1-Week Range:
$15.19
$18.54
52-Week Range:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
15.91 | 290.69M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.92 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.55 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.75 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.69 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.75 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How rising interest rates impact Avalo Therapeutics Inc. stock2025 Trading Recap & Capital Protection Trade Alerts - DonanımHaber
Avalo Therapeutics (NASDAQ:AVTX) Upgraded by Mizuho to "Strong-Buy" Rating - MarketBeat
Will Avalo Therapeutics Inc. (C6K0) stock announce special dividend2025 Market Outlook & Fast Moving Stock Trade Plans - DonanımHaber
Can Avalo Therapeutics Inc. (C6K0) stock survive global slowdownWeekly Stock Summary & Fast Entry Momentum Alerts - DonanımHaber
Breakout Move: Is Avalo Therapeutics Inc. stock a buy on dipsJuly 2025 Macro Moves & Precise Swing Trade Alerts - Улправда
This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Mizuho Initiates Coverage of Avalo Therapeutics (AVTX) with Outperform Recommendation - Nasdaq
Mizuho Initiates Avalo Therapeutics at Outperform With $39 Price Target - marketscreener.com
AVTX: Mizuho Initiates Coverage with Outperform Rating and $39 P - GuruFocus
Mizuho initiates Avalo Therapeutics stock with Outperform rating on HS drug potential By Investing.com - Investing.com South Africa
Mizuho initiates Avalo Therapeutics stock with Outperform rating on HS drug potential - Investing.com Canada
AVTX FinancialsIncome Statement - Quiver Quantitative
EBITDA per share of Avalo Therapeutics Inc – FWB:C6K0 - TradingView — Track All Markets
Avalo Therapeutics Earnings Notes - Trefis
Forecast Cut: How Avalo Therapeutics Inc stock valuations compare to rivalsEarnings Summary Report & Risk Controlled Swing Alerts - moha.gov.vn
Officer Riley Surrenders 637 Of Avalo Therapeutics Inc [AVTX] - TradingView — Track All Markets
Its Stock Has Paid Off Big Time For Avalo Therapeutics Inc - Setenews
With Avalo Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Why analysts maintain buy rating on Avalo Therapeutics Inc. (C6K0) stockWeekly Risk Report & Reliable Intraday Trade Alerts - Newser
Why Avalo Therapeutics Inc. (C6K0) stock could be next leaderGlobal Markets & Expert Curated Trade Setup Alerts - Newser
Why Avalo Therapeutics Inc. (C6K0) stock stays resilient2025 Support & Resistance & Risk Managed Investment Strategies - Newser
How buybacks impact Avalo Therapeutics Inc. stock value2025 Winners & Losers & Low Risk Investment Opportunities - Newser
Financial Comparison: InMed Pharmaceuticals (NASDAQ:INM) & Avalo Therapeutics (NASDAQ:AVTX) - Defense World
What hedge fund activity signals for Avalo Therapeutics Inc. stockDip Buying & Low Drawdown Trading Techniques - Newser
Is Avalo Therapeutics Inc. (C6K0) stock a top dividend aristocrat candidateNew Guidance & Safe Entry Momentum Tips - Newser
Published on: 2025-12-03 02:49:42 - Newser
Is Avalo Therapeutics Inc. (C6K0) stock overpriced at current multiplesWeekly Market Summary & Low Drawdown Investment Ideas - Newser
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $31.67 Average PT from Analysts - Defense World
Taking the lead: Avalo Therapeutics Inc (AVTX) - setenews.com
How Avalo Therapeutics Inc. stock benefits from strong dollarTrade Exit Summary & AI Based Buy and Sell Signals - Newser
Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView — Track All Markets
Is Avalo Therapeutics Inc. (C6K0) stock resilient in recession scenariosWeekly Risk Summary & Smart Allocation Stock Reports - Newser
What is the fair value of Avalo Therapeutics Inc. stock nowInflation Watch & Risk Controlled Stock Pick Alerts - Newser
How Avalo Therapeutics Inc. (C6K0) stock performs in easing cyclesGap Up & Community Consensus Trade Alerts - Newser
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avalo Therapeutics Reports Q3 2025 Financial Results - MSN
HC Wainwright Has Bearish Estimate for AVTX FY2025 Earnings - Defense World
Research Analysts Set Expectations for AVTX FY2025 Earnings - MarketBeat
How Avalo Therapeutics Inc. (C6K0) stock stacks up against competitorsJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
What valuation ratios show for Avalo Therapeutics Inc. (C6K0) stockRate Hike & Fast Momentum Stock Entry Tips - newser.com
How Avalo Therapeutics Inc. (C6K0) stock valuation compares with sectorMarket Activity Recap & Weekly Momentum Picks - newser.com
Is Avalo Therapeutics Inc. stock supported by strong cash flowsMarket Performance Recap & Smart Swing Trading Alerts - newser.com
Has Avalo Therapeutics Inc. formed a bullish divergenceJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Goldman Jonathan | Director |
Nov 14 '25 |
Sale |
14.33 |
11,367 |
162,937 |
0 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):